ZCube Announces the Second Edition of Open Accelerator
ZCube, Research Venture of the pharmaceutical group Zambon, launches the second edition of Open Accelerator, a fast track acceleration program for life science start-up projects.
Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that, following a selection process, could receive seed investment of up to €100.000 per project. Entries can be made following this link: http://www.openaccelerator.it.
The call for ideas will be open until 16th July 2017 and covers four main areas:
o Drug delivery systems (systems that allow better drug delivery either through particles or devices);
o Open source prototyping: medical devices, biomarkers, diagnostics (instruments and devices that allow safe and effective treatment, rehabilitation, prevention and diagnosis of diseases);
o Wearables and digital health (technological solutions through wearable devices that improve patient outcomes; technological platforms or mobile applications that offer new solutions to improve patient health);
o Big data (projects related to data analysis and solutions to improve medical treatment, develop personalized medicine, identify new markers for early diagnosis and reduce healthcare costs).
"For many years ZCube has been committed to developing partnerships in the field of scientific research through an open approach which aims at establishing relationships with international researchers, centers of excellence and universities around the world” declares Elena Zambon, President of Zambon Spa “Open Accelerator is an evolution of ZCube created to sustain scientific and digital innovation, the latter being a great agent of change of our times especially in the healthcare sector ".
A maximum of 30 projects will be selected take to part in the acceleration program that offers training and mentoring by specialized advisors including entrepreneurs, business angels, venture capitalists and experts from other disciplinary areas.
The acceleration path is open to researchers and scientists that have the ambition to conduct translational science. The program will be based on the established methodology of the Business Model Canvas that has been adopted by the National Science Foundation (NSF) and the National Institute of Health (NIH) in the United States.
Moreover, ZCube has recently signed a partnership with IAB - Italian Angels for Biotech, the first association of business angels exclusively dedicated to Life Sciences - and Innogest, a leading venture capital fund operating in Italy and in Europe. Advisors from IAB and Innogest, along with other international experts, will take part in the acceleration path providing mentoring and advice to guide start uppers through business model creation and go-to-market strategy development. At the end of the program the most innovative ideas could receive a seed investment of up to € 100.000, which will serve as an important catalyst to enter the market.
"Open Accelerator is an arena in which researchers and entrepreneurs are helped to build the foundation of their startups and to prepare for the challenge of reaching out to venture capital that will finance the next stages of their projects” concludes Elena Zambon “Our accelerator program will become the heart of Open Zone, the scientific campus located near Milan where science oxygenates business. Open Zone is a community of 600 people where new projects, talent and proven expertise come together to help affirm Italy’s role as an ideal country for business innovation. "
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018